Peter Clark, MD, discusses key updates to NMIBC guidelines, including revisions to risk stratification, the emerging role of biomarkers, and how to navigate treatment options for BCG-unresponsive disease.
|Videos|June 17, 2022
Study explores relationship between testosterone and frailty in the operative setting
Author(s)Urology Times staff
Advertisement
In this video, Joshua Halpern, MD, discusses the abstract, “Association of low testosterone and frailty among veterans undergoing cancer surgery,” which he presented at the 2022 AUA Annual Meeting. Halpern is an assistant professor of urology at Northwestern University Feinberg School of Medicine in Chicago, Illinois.
Advertisement
Related to this article
The AMA issued separate codes for subfascial and subcutaneous implantation of a tibial neuromodulation device.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Heather Florio joins to discuss the potential role of supplements in pelvic and sexual health.
John P. Sfakianos, MD, discusses how ctDNA can be optimally integrated into bladder cancer clinical trials.
A recap of the FDA submissions and regulatory decisions in urology from September 2026.
Robert J. Motzer, MD, discusses the significance of the belzutifan plus lenvatinib approval, adverse event management with the combination, and the evolving role of HIF-2α inhibition in ccRCC.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
Advertisement
Advertisement
Trending on Urology Times
1
John Sfakianos, MD, on integrating ctDNA into bladder cancer trials
2
FDA updates in urology: September 2026
3
AMA issues Category I CPT codes for implantable tibial neuromodulation in UUI
4
Enzalutamide plus salvage radiotherapy associated with improved PFS in high-risk BCR
5